Medical network May 9 - in a year the number of new drug approvals listed are usually regarded as a barometer of drug firms productivity, EP Vantage for nearly five years to new drugs to market recently generalizes the main company, and analyzed the great achievements have been made in the company. 

 

The analysis found that Merck had the top spot in five years with 10 new drugs approved by the FDA. Novartis and Glaxosmithkline each have nine new drugs on the list, tied for second. Of course, not all new drugs are developed by these companies themselves, and many are acquired by other companies or acquired through acquisitions. But whatever the source of the new drugs, they still make a huge profit. By contrast, Sanofi and Astrazeneca are at a low birth date. 

 

 

 

Nearly five years of data 

 

The analysis compiled from 2012 to 2016 by the FDA drug evaluation and research (CDER) and biologics evaluation and research center (CBER) approval of new drugs, some blood products and contrast agents are not included. In addition, in the analysis, if a particular medicine before approval has been sold or licensed to other companies, the acquirer or authorized parties will be regarded as the original company of new drugs, even if authorized or takeover activity occurred shortly before getting listed on the FDA approval. 

 

For example, the optimal paid (Eucrisa) listed on the FDA approval for its first six months was sold to Pfizer (Pfizer), Roche (Roche) pyrazole fini ketone (Esbriet) 2 weeks before the public permission acquired InterMune biopharmaceutical company, thus become the master of Esbriet. 

 

Based on these statistical rules, the analysis found that over the past five years, the number of new drugs to be listed in the city has doubled. This is, of course, a simple assessment that focuses on the market potential of new drugs, which are more important than quantity. 

 

 

 

In terms of sales expected for the new drug in 2022, the company stands out again, with total sales of 10 new drugs listed in the past five years topping the list. And according to the evaluation results of EvaluatePharma company, expects sales of these products accounted for 41% of total sales of prescription drugs in the company, compared with some drug companies, the considerable proportion. 

 

Keytruda is one of the most important anti-cancer drugs that has been listed in the city for nearly five years, with sales accounting for a large percentage of the company's total annual sales. Keytruda's expected sales of $12 billion in 2022 will be the world's third best-selling drug. 

 

Bristol-myers Squibb and roche followed. Listed among them, the BMS in recent five years was the most blockbuster drugs immune checkpoint inhibitors worth of single (Opdivo) and blood thinners elle (Eliquis), four blockbuster products and roche proud to this bead single (Perjeta) resistance, athar zhu (Tecentriq) resistance, Gazyva, by bead sheet resistance (Kadcyla). 

 

But overall, BMS is better. Its new drug sales account for about two-thirds of its total annual sales over the past five years. Many people think BMS is too reliant on new drugs, so the company is under pressure to expand research and development lines. 

 

Gilead needs new blood 

 

Astrazeneca and sanofi are at the bottom of the list, and their new drugs have little effect on the company's overall sales. On May 2, astrazeneca's tumor immunisation drug durvalumab was approved by the FDA for the treatment of patients with advanced or metastatic urothelial carcinoma, which added a "new force". In late march, the FDA approved Dupixent's application for a listing, which was a relief for sanofi, but there are still plenty of people who think the company urgently needs to increase its revenue stream. 

 

Noteworthy and Gilead (Gilead), its dominance in hepatitis c drug market decline, and have yet to find can meet potential new drugs, in research and development the company is not prominent. 

 

The figures are a partial snapshot of the complexity of the current research and development of drugs, which many believe have improved in recent years. Obviously, every business has its own difficulties, but they all need to solve the problem of pricing new drugs, which depends on specific medical needs and product specificity.